Assessment of the topoisomerase I gene copy number as a predictive biomarker of objective response to irinotecan in metastatic colorectal cancer.

Scandinavian journal of gastroenterology (2014 Jan)
issue 1 p. 84-91 (issn:1502-7708)

DNA topoisomerase I is a putative biomarker of irinotecan efficacy with clinical associations previously demonstrated at the protein level. The purpose of the present study was to perform the first clinical investigation of the association between the DNA topoisomerase I gene (TOP1) copy number and objective response following irinotecan treatment in patients with metastatic colorectal cancer.

Forfattere: Nygård SB, Christensen IJ, Nielsen SL, Nielsen HJ, Brünner N, Spindler KL

Se på Pub MED

Print Friendly, PDF & Email

Donation / Partnerskab

Er du interesseret i at donere til vores forskning som privatperson, virksomhed eller forening?

Dit navn *

Din e-mail *

Dit tlf. nummer

Din besked *

  Emne

Kontaktoplysninger

ColoRectal Cancer Research

Gastroenheden, Hvidovre Hospital

Kettegård Allé 30

2650 Hvidovre

Email: info@colorectalcancer.dk